However, Celldex is also developing products to treat ultra-rare orphan diseases, and if successful, this fact could transform the company and add long-term gains to your portfolio.
http://www.fool.com/investing/general/2013/10/15/can-this-orphan-program-create-even-larger-gains.aspx
http://www.fool.com/investing/general/2013/10/15/can-this-orphan-program-create-even-larger-gains.aspx
No comments:
Post a Comment